Corcept Therapeutics is expected to report Q3 2026 revenue of $215.42 million and EPS of $0.68, with the current stock price of $56.42 trading below the average analyst target of $68.50. Investors are primarily focused on the sales trajectory of Korlym, the company's treatment for Cushing's syndrome, which remains the sole commercial revenue driver.
Market attention is also centered on updates regarding the Relacorilant clinical pipeline following the completion of the GRACE trial and progress toward a New Drug Application. Strong operational performance and cash flow from Korlym are seen as essential to funding Corcept's expanding portfolio of selective cortisol modulators.